Interview with the Innovators

Criteria Used to Guide Treatment Decisions and Choice of Therapeutic Agents in Patients with Relapsed or Refractory Follicular Lymphoma



Tycel J. Phillips, MD
Clinical Associate Professor
University of Michigan Rogel Cancer Center
Ann Arbor, MI
Peg Rummel, MHA, RN, OCN, NE-BC
Oncology Nurse Navigator
Hematology/Head & Neck Clinical Services
University of Pennsylvania Abramson Cancer Center
Philadelphia, PA
Andrew D. Zelenetz, MD, PhD
Medical Oncologist and Medical Director
Quality Informatics, Memorial Sloan Kettering Cancer Center Professor of Medicine, Weill Cornell Medical College Chair, Lymphoma Research Foundation, Scientific Advisory Board
New York, NY

Dr Andrew Zelenetz examines the various criteria used in individual patients with relapsed or treatment-refractory follicular lymphoma and how they help determine the trigger for and timing of initiating antitumor therapies. Dr Tycel Phillips expands on how applying such criteria may best guide the oncologist to choose specific treatment options, such as certain classes of currently available (FDA-approved) drugs in monotherapy or in combination, especially in a community-based clinical setting.

Supported by

Related Articles